伊贝沙坦治疗轻、中度高血压病疗效观察

目的 :评价伊贝沙坦对轻、中度高血压病的降压疗效和安全性。方法 :既往未服用降压药的 2 3 9例轻、中度高血压病患者分为 2组 ,采用随机、开放、平行对照研究 ,分别每日口服 1次伊贝沙坦 150～ 3 0 0mg(伊贝沙坦组 )或依那普利5～ 10mg(依那普利组 ) ,治疗 8周 ,观察用药前后坐位血压 ,对比用药前后血生化、血尿常规检查结果 ,记录不良反应。结果 :伊贝沙坦组有效率 84.3 5% ,依那普利组 69.3 % ,两组比较无显著性差异 (P >0 .0 5) ;伊贝沙坦和依那普利组分别有 2 6.96%和 54.3 8%患者加用利尿剂。 8周伊贝沙坦组及依那普利组SeSBP/SeDBP均下降 ,其中 2、4、6、8周伊贝沙坦组SeDBP的下降幅度大于依那普利组 ,两组有显著性差异 (4周P <0 .0 5,2、6、8周P均 <0 .0 1) ;依那普利组咳嗽 14例 ,发生率 12 .3 %。结论 :伊贝沙坦 150～ 3 0 0mg/d治疗轻、中度高血压病的有效率近似于依那普利 5～ 10mg/d ,但耐受性好于依那普利

Efficacy and Tolerability of Irbesartan in Patients With Mild to Moderate Essential Hypertension

Objective:To evaluate the efficacy and tolerability of irbesartan by comparing the antihypertensive effect and safety of irbesartan with enalapril. Me thods: 229 patients with mild to moderate hypertension, having not been treated with antihypertensive medicine before, were randomly divided into two groups. One gro up was treated with irbesartan 150～300mg/d(irbesartan group), the other gr oup w ith enalapril 5～10mg/d(enalapril group)for 8 weeks.Sitting blood pressure and l aboratory examination of the patients were observed at baseline and post-treatme nt. Adverse reactions were recorded.Results: Effective rate was 84.3% in irbesartan group and 69.3% in enalapril group(P>0.05).There was no significant difference in response rates between two groups. The addition of diuretic was required in 26.96% of patients on irbesartan group and 54.38% of p atients on enalapril group.At the end of 8 weeks SeSBP/SeDBP was decreased in two gr oups.The decreace of SeDBP was more significant at the end of 2,4,6 and 8 weeks in irbesatan group than that in enalapril group. Conclusion:Irbesartan 150～300mg/d is as effective as and much more tolerated than enalapril 5～10mg/d in patients with mild to moderate essential hypertension.